➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Johnson and Johnson
AstraZeneca
Merck
Mallinckrodt

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Generic Companies with Tentative Approvals for: Eugia Pharma


Email this page to a colleague

« Back to Dashboard

Eugia Pharma Generic Filers with Tentative Approvals

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Applicant Generic Name NDA Strength Dosage Form
Eugia Pharma bortezomib 212825 3.5MG/VIAL INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
Eugia Pharma carfilzomib 210823 60MG/VIAL POWDER;INTRAVENOUS
>Applicant >Generic Name >NDA >Strength >Dosage Form

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Medtronic
Mallinckrodt
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.